SGRY (Surgery Partners, Inc.) — AI Stock Analysis & Recommendation

Research of August 24, 2026 · Healthcare / Services-General Medical & Surgical Hospitals, NEC

TradeFlare's AI research teams rate SGRY a HOLD. The latest price is $14.55.

The research plan

• Entry: $13.95
• Time horizon: days

The current market conditions and the stock's neutral technical and fundamental outlook do not warrant a trade.

Why

Despite the presence of insider buying, the overall neutral stance of the technical, fundamental, and sentiment teams, coupled with a high risk score and conflicting technical signals, prevents a BUY recommendation. The stock's high debt, volatility, and short interest present substantial risks that outweigh the current positive signals in a neutral market. Therefore, a HOLD is the most prudent decision.

What could push SGRY higher

• Insider buying by DeLuca Teresa provides a positive fundamental signal.
• Q2 earnings beat expectations, indicating potential operational improvements.
• The company operates in a growing outpatient surgical market.

Key risks for SGRY

• High debt load and leverage pose significant financial risk.
• Deep drawdown and high volatility suggest a history of price instability.
• Elevated short interest indicates strong bearish sentiment and potential for a short squeeze, but also significant downside risk.

What each AI research team found

Fundamental team: Neutral · valuation: speculative

Surgery Partners presents a speculative opportunity with a strong market position and positive TTM free cash flow, but current unprofitability and high debt create significant risks. The low P/S ratio and positive analyst sentiment suggest potential upside, but the financial health concerns warrant a neutral stance until profitability and debt management improve.

• The company operates in a growing outpatient surgical market with a significant national presence, but faces challenges with current unprofitability and high debt levels.
• Despite a modest 2.7% YoY revenue growth, the company has a negative net margin (-2.63%) and trailing EPS (-0.69).
• The Price-to-Sales ratio (0.54x) is significantly below industry and peer averages, suggesting potential undervaluation on a revenue basis.

Technical team: Neutral

SGRY is currently in a neutral consolidation phase near a key support level ($13.80). While insider buying provides a positive fundamental context, technical indicators present a mixed picture with short-term bearish moving averages conflicting with oversold momentum signals. The stock is likely to remain range-bound until a clear breakout or breakdown occurs.

• Price is consolidating near support ($13.80) with short-term moving averages suggesting caution, indicating a sideways trend.
• Below-average volume and spikes on both up and down days suggest a lack of conviction and a neutral outlook.
• Mixed signals with neutral RSI, bearish MACD, and oversold Stochastic Oscillator indicate potential for a bounce but no clear trend.

Sentiment team: Neutral

Surgery Partners (SGRY) exhibits a neutral sentiment, with recent Q2 earnings beats and insider buying providing some positive momentum. However, this is counterbalanced by a wider-than-expected loss, historical stock weakness, and a recent analyst downgrade, creating a balanced outlook.

• Q2 earnings beat expectations, with positive signals on valuation and strategic focus, but tempered by a wider-than-expected loss and stock price decline despite positives
• Neutral sentiment driven by Q2 earnings beat and analyst optimism, offset by concerns over a rejected takeover offer and potential valuation traps
• Neutral sentiment due to Q2 earnings beat and institutional accumulation, but a recent downgrade and historical stock weakness create caution.

Risk team: High

SGRY presents a high-risk profile due to its significant debt, historical price volatility, deep drawdowns, and current unprofitability. The high short interest further amplifies these concerns. Given the confluence of these factors, a small position size with stringent risk management is recommended.

• High Debt Load and Leverage: The company carries a substantial debt load with a high debt-to-equity ratio (117.26%) and a low interest coverage proxy (1.66x), making it vulnerable to financial distress and rising interest rates.
• Deep Drawdown and High Volatility: SGRY has experienced a severe 1-year drawdown of -74.5% and exhibits consistently high volatility across different timeframes, indicating significant price instability and potential for further sharp declines.
• High Short Interest: Elevated short interest and days to cover suggest strong bearish sentiment and a heightened risk of price depreciation if negative catalysts emerge, despite potential for short squeezes.

SGRY at a glance

Market value	$1.8B
Revenue growth (year over year)	19.3%
Profit margin	7.2%
Debt / equity	2.18

Every AI call on SGRY since August 12, 2026, and what happened next (6 calls) →

Research of August 24, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.